The global pharmaceutical portfolio today reflects a greater prevalence of large molecule drugs, expansion in the number of personalized products, and a rise in orphan disease treatments. Over 1,000 biologics have been approved worldwide and more than 8,000 are in development to help address unmet healthcare needs.
To meet therapy production demands, the industry needs to have the right capacity, in the right locations. Increasingly, single‑use technologies are being seen as the solution to flexibly and cost‑effectively address many of the challenges around creating biologics manufacturing capacity. And it’s the fastest way to bring capacity online.
If you, as a pharmaceutical company or contract manufacturing organization, are looking to produce biologics using single‑use technologies, there are many ways to approach the challenge of creating cGMP biomanufacturing capacity.
Contract development and manufacturing organization Fujifilm Diosynth identified five key considerations to inform their biologics manufacturing capacity expansion plans. Having already successfully implemented GE Healthcare’s BioProcess single‑use platform at their site in North Carolina, USA, they decided to duplicate this capacity at their Billingham, UK, site.
Working in close partnership with GE Healthcare, Fujifilm Diosynth was able to bring online the UK’s first cGMP single‑use manufacturing facility in just 14 months. Details of how the options were assessed and the secrets to their success can be found in this eBook.